/

Società

Ge

Non verificato

Genentech

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

109 comunicati stampa

Guarda tutti i comunicati

25/10/2026

Oncologia

Salute

Medicina - Varie

Sanità

Farmaceutica

Biotecnologia

Industria

Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer

Fonte

Emittente

1.00

0

23/10/2026

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Eventi

Industria

Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)

Fonte

Emittente

1.00

0

21/10/2026

Oncologia

Salute

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Fiere

Industria

Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

Fonte

Emittente

1.00

0

19/10/2026

Oncologia

Salute

Biotecnologia

Medicina - Varie

Farmaceutica

Eventi

Industria

Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio

Fonte

Emittente

1.00

0

16/10/2026

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Sanità

Ottica

Industria

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Fonte

Emittente

1.00

0

10/10/2026

Scienza

Biotecnologia

Farmaceutica

Ottica

Salute

Igiene alimentare

Medicina - Varie

Industria

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Fonte

Emittente

1.00

0

09/10/2026

Industria

Oncologia

Salute

Igiene alimentare

Medicina - Varie

Farmaceutica

Biotecnologia

FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer

Fonte

Emittente

1.00

0

01/10/2026

Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends

Fonte

Emittente

1.00

0

01/10/2026

Eventi

Industria

Scienza

Biotecnologia

Farmaceutica

Ottica

Salute

Igiene alimentare

Medicina - Varie

Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

Fonte

Emittente

1.00

0

01/10/2026

Eventi

Industria

Oncologia

Salute

Igiene alimentare

Medicina - Varie

Farmaceutica

Biotecnologia

Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0